Jardiance Tablet, Film Coated
NDC Package 55154-0412-8
Package Information
Jardiance (empagliflozin) tablets is jARDIANCE is indicated:•to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure.•to reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression.•to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.•as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. This formulation utilizes a tablet, film coated delivery system. Marketed by Cardinal Health 107, Llc, this product is identified by NDC 55154-0412 and is authorized under FDA application NDA204629.
Identification & Billing
- RxCUI: 1545658 - empagliflozin 10 MG Oral Tablet
- RxCUI: 1545664 - Jardiance 10 MG Oral Tablet
- RxCUI: 1545664 - empagliflozin 10 MG Oral Tablet [Jardiance]
- RxCUI: 1545666 - empagliflozin 25 MG Oral Tablet
- RxCUI: 1545668 - Jardiance 25 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 55154 - Cardinal Health 107, Llc
- 55154-0412 - Jardiance
- 55154-0412-8 - 990 TABLET, FILM COATED in 1 BOTTLE, PLASTIC
- 55154-0412 - Jardiance
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 55154-0412-8 identifies a specific commercial package of 990 tablet, film coated in 1 bottle, plastic of Jardiance, a human prescription drug labeled by Cardinal Health 107, Llc. This product is billed for "EA" each discreet unit and contains an estimated amount of 990 billable units per package. This tablet, film coated is formulated for oral use and contains empagliflozin as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Cardinal Health 107, Llc on August 01, 2014. The current certification is valid through December 31, 2027.
How is this Cardinal Health 107, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 55154041208. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 990 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.